Alabama lawyer claims Sandoz should pay $170M for overcharging state Medicaid

2 March 2009

A US lawyer based in Alabama has filed a lawsuit claiming payments of up to $170.0 million from Sandoz, the generics arm of Swiss drug major  Novartis, on the basis that its Medicaid reimbusement prices in the  state are too high. Jere Beasley argues that the firm has been  overcharging the health care insurer for more than a decade. A lawyer  for Sandoz retorted by saying that the firm had, in fact, saved the  state millions of dollars by selling low-cost generic versions of  popular drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight